<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03104894</url>
  </required_header>
  <id_info>
    <org_study_id>0137-13-BRZ</org_study_id>
    <nct_id>NCT03104894</nct_id>
  </id_info>
  <brief_title>The Effect of Meibomian Glands Massage on Signs and Symptoms of Dry Eye</brief_title>
  <official_title>The Effect of Meibomian Glands Massage on Signs and Symptoms of Dry Eye</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Barzilai Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Barzilai Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims to investigate whether combined treatment of MGD massage and artificial tears&#xD;
      will improve signs and symptoms of dry eye compared to artificial tears alone.&#xD;
&#xD;
      The meibomian glands secrete meibum which is the oily component of the tear film layer. The&#xD;
      meibum plays a pivotal role in preventing tear evaporation and smoothening the tears film .&#xD;
&#xD;
      Meibomian gland dysfunction is a common condition that affects 39%-50% of the population. It&#xD;
      is part of inflammatory disease of the eyelids called blepharitis. Associated syndromes are&#xD;
      rosacea and dry eye syndrome .&#xD;
&#xD;
      Sign and symptoms are: irritation, hyperemia, burning sensation, photophobia, epiphora and&#xD;
      blur.&#xD;
&#xD;
      Spectrometry analysis shows change it the fatty acids conformation such as increase in levels&#xD;
      of branched-chain fatty acids and decrease in saturated fatty acids .&#xD;
&#xD;
      Subsequently the clotted meibum results in glands blockage that can be graded in 0-4 grade&#xD;
      scale: grade 2- meibum secretion thick and oily, grade 3- meibum secretion&#xD;
      granular-toothpaste like.&#xD;
&#xD;
      Although MGD is not often accompanied with inflammatory signs it is a common cause for&#xD;
      evaporative dry eye.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In order to investigate the relation between meibomian gland massage outcomes and signs and&#xD;
      symptoms of dry eye, randomized prospective study will be conducted. Patients, who arrive to&#xD;
      Barzilai Medical Center out patients' clinic, are diagnosed with MGD 2-3 and signed informed&#xD;
      consent form shall be included in the trial, then randomized to study group or control group.&#xD;
&#xD;
      The study group will receive meibomian glands massage and artificial drops PRN, whereas the&#xD;
      control group will receive sham massage and artificial drops. Each visit at the clinic will&#xD;
      include dry examinations and questionnaire.&#xD;
&#xD;
      Follow up examination are due after one week, monthly visits up to 4 months, then after half&#xD;
      year, 8 months and one year.&#xD;
&#xD;
      Statistical methods: in order to evaluate to treatment effect T-Test analysis will be&#xD;
      calculated, significant result is when P&lt;0.05.&#xD;
&#xD;
      Data will be recorded into to electronic sheets. Subjects' confidentiality will be assured by&#xD;
      masking any identifying details and a random number will be assigned prior results analysis&#xD;
      stage&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2015</start_date>
  <completion_date type="Actual">December 2017</completion_date>
  <primary_completion_date type="Actual">September 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>patient will be assigned to the study/control group by randomization soft ware. The results will be documented and kept by the doctor who preforms the meibomian glands massage/ sham massage. All patients will receive study number. Follow up examination will be preformed by another doctor.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement in Tear Break up Time TBUT.</measure>
    <time_frame>1 month</time_frame>
    <description>Tear break up time will be measured in seconds. The score is expected to be higher.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Improvement in Ocular Surface Disease Index questionnaire score (OSDI)</measure>
    <time_frame>1 month</time_frame>
    <description>OSDI score will be calculated according a formula: (sum of scores) X 25 divided by the number of questions answered. The score is expected to be lower.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>MGD-Meibomian Gland Dysfunction</condition>
  <arm_group>
    <arm_group_label>Study Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The study group will receive meibomian glands massage and artificial drops PRN</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>The control group will receive sham meibomian glands massage and artificial drops PRN.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Meibomian Glands Massage</intervention_name>
    <description>Meibomian gland expression</description>
    <arm_group_label>Study Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Sham Meibomian Glands Massage</intervention_name>
    <description>Touching the eyelids gently</description>
    <arm_group_label>Control Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Meibomian Massage device</intervention_name>
    <description>Meibomian glands expression with applicator</description>
    <arm_group_label>Study Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult Individuals (ageâ‰¥18Y) with MGD levels 2-3 that are capable to make an informed&#xD;
             decision about their participation in the trial.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  pregnant women, subjects who received prior Meibomian gland massage.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Barzilai Medical Center</name>
      <address>
        <city>Ashqelon</city>
        <state>Is</state>
        <zip>78278</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <study_first_submitted>March 14, 2017</study_first_submitted>
  <study_first_submitted_qc>April 2, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 7, 2017</study_first_posted>
  <last_update_submitted>January 19, 2018</last_update_submitted>
  <last_update_submitted_qc>January 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meibomian Gland Dysfunction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

